

Abstract Type : Poster

Abstract Submission No. : PO-1103

Comparison of circuit patency and exchange rates between the original products and the generic versions of Nafamostat mesilate in critically ill adults receiving continuous renal replacement therapy

Haesu Jeon, Jisu Kim, Yuri Cheon, Gayoung Sung, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim

Department of Internal Medicine-Nephrology, Kosin University Gospel Hospital, Korea, Republic of

Objectives: The generic versions have the same main component as the original products. But, due to the difference in additives or the level of impurities, it is questionable the the generic versions are completely identical to the original products. Nafamostat mesilate has been widely used as an anticoagulation in continuous renal replacement therapy (CRRT) with hemorrhagic diathesis. In this study, we performed comparison of circuit patency and exchange rates between the original products and the generic versions of Nafamostat mesilate in acute kidney injury patients receiving continuous renal replacement therapy

Methods: We have conducted retrospective studies to compare the original product of nafamostat mesilate (n=732) with the generic version (n=328) on the CRRT running time.

Results: CRRT filter life time of the generic version group was shorter than that of original product group although that was not significantly.

Conclusions: When generic versions of nafamostat mesilate are adopted in a hospital formulary, it must be emphasized that the effect these versions may be not completely identical to that of the original products.

Table 1. The numbers of patients showing assessment of eligibility and enrollment in this study

Total number of patients	1255
Excluded patients from Nafamostat mesilate (NM) group	146
Patients' number of NM group in analysis	732
Excluded patients from generic group	49
Patients' number of generic group in analysis	328

Table 2. Characteristics of Patients according to anticoagulants

No. of patients	Nafamostat mesilate (n= 732)	Generic (n= 328)	P value
Male:Female	424/308	170/178	0.558
Age, year (range)	64.1 ± 14.9	62.5 ± 13.6	0.309
CKD (%)	31.1	35.0	0.078
Death (%)	51.3	42.1	0.256
Cause of death (%)			
MOF	60.1	52.2	0.416
Cardiac	22.3	29.6	
Cerebral	6.5	5	
Respiratory	7.5	8.5	
Tumor recurrence	3.6	4.7	
Clinical setting			0.732
Medical (%)	72.3	73.2	
Surgical (%)	27.7	26.8	
APACHE III score	83.3 ± 34.1	82.9 ± 37.1	0.823
Oliguria (%)	43.3	42.6	0.647
Mechanical ventilation (%)	58.6	61.3	0.259
Vasoactive drug (%)	55.1	56.3	0.725
Conventional HD (%)	15.5	16.3	0.123
Sepsis (%)	52.3	54.3	0.637